

---

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K/A**

---

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**DATE OF REPORT  
(DATE OF EARLIEST EVENT REPORTED)**

**December 3, 2008**

---

**ASTRO-MED, INC**

**(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)**

---

**COMMISSION FILE NUMBER      0-13200**

**Rhode Island**

(State or Other Jurisdiction of Incorporation or  
Organization)

**05-0318215**

(IRS Employer Identification Number)

**600 EAST GREENWICH AVENUE, WEST WARWICK, RI 02893**  
**(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)**

**(401-828-4000)**

**(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)**

---

## ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On December 3, 2008, Astro-Med, Inc. (the "Company") issued a press release in which it disclosed unaudited financial information related to third quarter consolidated earnings. The Exhibit filed with Form 8-K dated December 3, 2008 was not the final release issued by the Company and contained incorrect numbers for the Company's current ratio and current liabilities. A copy of the correct press release (as originally issued) is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

## ITEM 8.01 OTHER EVENTS

On December 4, 2008, the Company conducted a conference call to review its third quarter earnings release. On the call, the Company updated its previously issued earnings guidance for fiscal year 2009, indicating an expect range of annual sales of \$74-\$76 million and earnings per share of \$0.45 to \$0.50. The webcast can be accessed for the next five days at [www.Astro-MedInc.com/webcast](http://www.Astro-MedInc.com/webcast).

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

## ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

### (c) Exhibit

Exhibit no.	Exhibit
99.1	Press Release dated December 3, 2008

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned thereunto duly authorized.

**DATE: December 4, 2008**

**ASTRO-MED, INC.**

**By:** /s/ Joseph P. O'Connell

\_\_\_\_\_  
Joseph P. O'Connell  
Senior Vice President, Treasurer and Chief Financial Officer

INDEX TO EXHIBITS


**Exhibit No.**

**Exhibit**

99.1

Press Release Dated December 3, 2008

# PRESS RELEASE



600 East Greenwich Avenue  
West Warwick, Rhode Island 02893

*For Immediate Release*

**Contact:** Albert W. Ondis, CEO  
Joseph P. O'Connell, CFO  
Astro-Med, Inc.  
(401) 828-4000  
[www.astro-medinc.com](http://www.astro-medinc.com)

December 3, 2008

## **Astro-Med Reports Third Quarter Financial Results; Directors Declare Regular Cash Dividend**

West Warwick, RI, December 3, 2008 -- Astro-Med, Inc. (NASDAQ:ALOT) reports net income of \$649,000, equal to 9 cents per diluted share, on sales of \$17,681,000 for the Third Quarter ended November 1, 2008. For the corresponding period of the prior year, Astro-Med reported net income of \$1,562,000, equal to 21 cents per diluted share, on sales of \$19,139,000. Net income in the prior year quarter included a tax benefit of approximately \$446,000, or 6 cents per diluted share, due to favorable resolution of certain income tax examinations.

For the nine-month period of the current fiscal year, Astro-Med reported net income of \$2,701,000, equal to 36 cents per diluted share on sales of \$56,152,000, compared to net income of \$2,969,000, equal to 39 cents per diluted share, on sales of \$54,241,000 in the comparable nine-month period of the prior fiscal year. Net income for the nine-month period of the prior fiscal year included a tax benefit of approximately \$446,000, or 6 cents per diluted share, due to the favorable resolution of income tax examinations.

Commenting on the results, Albert W. Ondis, Chief Executive Officer, said: "We are pleased to have achieved solid Third Quarter results despite the difficult current business climate. We continued our aggressive new product development program and maintained our renowned high level of customer support, while at the same time strengthening our powerful balance sheet by increasing our cash and marketable securities position to \$22,093,000, improving our current ratio to 6.08 to 1, and remaining debt free. Our Gross Profit margins remained healthy at 43.3% and income from operations exceeded \$1 million. And, we continued to pay cash dividends at the annual rate of 24 cents per share."

Results for the nine month period of the current fiscal year reflect sales increases of 3.5%, gross profit increases of 6.4%, and an operating income increase of 19.1%. Favorable foreign exchange currency rates added approximately \$798,000 to this

year's nine-month sales. Favorable foreign exchange currency rates declined approximately \$118,000 in this year's Third Quarter sales.

New orders in the Third Quarter matched the first quarter's orders at \$18,301,000. While sales of Test & Measurement equipment increased by 9.3%, Third Quarter revenue from sales of Ruggedized cockpit printers was impacted by production delays in the Airbus 380 and Boeing 787 aircraft. QuickLabel Systems brand sales were affected by our customers' cautious attitude toward making new purchases. Grass Technologies brand sales of sleep and most neurological instruments were strong in the Third Quarter, up 30.8% from the prior year. However, sales of Grass long-term monitoring products and products aimed at research applications lagged behind the previous year.

"We are very confident in Astro-Med's future prospects with our industry-leading new and existing products, solid base of existing customers, strong profit margins, secure balance sheet, and worldwide recognition of our Astro-Med Test & Measurement, QuickLabel Systems, and Grass Technologies brands. Our organization is committed to success, and the Company will continue on its path of growth and profitability," said Ondis.

#### **Astro-Med Directors Declare Regular Cash Dividend**

On November 17, 2008, the Directors of Astro-Med declared the regular quarterly cash dividend of 6 cents per share, payable on January 2, 2009 to shareholders of record on December 12, 2008.

#### **Third Quarter Conference Call to be held Thursday, December 4, 2008**

The Astro-Med Third Quarter conference call will be held on Thursday, December 4, 2008, at 11:00 AM EST. It will be broadcast in real time on the Internet. We invite investors and analysts to participate in the conference call by dialing in to 800-257-7087 or by listening to the web cast at [www.Astro-MedInc.com/webcast](http://www.Astro-MedInc.com/webcast). The webcast will be accessible for up to five days following the call.

### **Astro-Med, Inc.**

#### **Consolidated Statements of Operations In Thousands Except for Per Share Data (Unaudited)**

	<b>Three-Months Ended</b>		<b>Nine-Months Ended</b>	
	<b>November 1, 2008</b>	<b>November 3, 2007</b>	<b>November 1, 2008</b>	<b>November 3, 2007</b>
Net Sales	\$17,681	\$19,139	\$56,152	\$54,240
Gross Profit	7,647	8,372	24,516	23,049
	43.3%	43.7%	43.7%	42.5%
Operating Expenses:				
Marketing & Selling	4,164	4,270	12,928	12,618
Research & Development	1,254	1,184	3,680	3,417
General & Administrative	<u>1,140</u>	<u>1,180</u>	<u>3,595</u>	<u>3,392</u>
	6,558	6,634	20,203	19,427
Operating Income	1,089	1,738	4,313	3,622
	6.2%	9.1%	7.7%	6.7%

Other Income (Expense), Net	<u>(237)</u>	<u>170</u>	=	<u>632</u>
Income Before Taxes	852	1,908	4,313	4,254
Income Tax Provision	<u>203</u>	<u>346</u>	<u>1,612</u>	<u>1,285</u>
Net Income	<u>\$ 649</u>	<u>\$ 1,562</u>	<u>\$ 2,701</u>	<u>\$ 2,969</u>
Net Income Per Share - Basic	<u>\$ 0.09</u>	<u>\$ 0.23</u>	<u>\$ 0.39</u>	<u>\$ 0.43</u>
Net Income Per Share - Diluted	<u>\$ 0.09</u>	<u>\$ 0.21</u>	<u>\$ 0.36</u>	<u>\$ 0.39</u>
Weighted Average Number of Common Shares - Basic	7,005	6,912	6,979	6,881
Weighted Average Number of Common Shares - Diluted	7,471	7,510	7,478	7,552
Dividends Declared Per Common Share	\$ 0.06	\$ 0.05	\$ 0.18	\$ 0.15

**Selected Balance Sheet Data  
In Thousands  
Unaudited**

	<u>As of November 1, 2008</u>	<u>As of January 31, 2008</u>
Cash & Marketable Securities <sup>(1)</sup>	\$22,093	\$17,556
Current Assets	\$47,663	\$48,384
Total Assets	\$61,846	\$61,699
Current Liabilities	\$7,837	\$8,973
Shareholders' Equity	\$51,406	\$49,355

<sup>(1)</sup> Includes investment securities classified as non-current

**About Astro-Med, Inc.**

Astro-Med, Inc. is a leading manufacturer of specialty high tech printing systems, electronic medical instrumentation, and test and measurement instruments. Astro-Med, Inc. products are sold under the brand names Astro-Med<sup>®</sup>, Grass<sup>®</sup> Technologies and QuickLabel<sup>®</sup> Systems and are employed around the world in a wide range of aerospace, medical, military, industrial, and packaging applications. Astro-Med, Inc. is a member of the Russell Microcap<sup>®</sup> Index. Additional information is available by visiting [www.Astro-MedInc.com](http://www.Astro-MedInc.com).

**Safe Harbor Statement**

*This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include those mentioned in Astro-Med's FY2008 annual report and its annual and quarterly filings with the Securities and Exchange Commission.*